Novartis Reports Phase 2 Data for Venetoclax in Rheumatoid arthritis

Novartis today announced Phase 2 results for venetoclax in patients with rheumatoid arthritis. The study demonstrated that venetoclax reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of rheumatoid arthritis and support the continued development of venetoclax in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.